These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 6655467)
1. Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain. Wong DT; Bymaster FP; Reid LR; Fuller RW; Perry KW; Kornfeld EC J Neural Transm; 1983; 58(1-2):55-67. PubMed ID: 6655467 [TBL] [Abstract][Full Text] [Related]
2. Elevation of acetylcholine levels in striatum of rat brain by LY163502, trans-(-)-5,5a,6,7,8,9a,10-octahydro-6-propylpyrimido less than 4,5-g greater than quinolin-2-amine dihydrochloride, a potent and stereospecific dopamine (D2) agonist. Bymaster FP; Reid LR; Nichols CL; Kornfeld EC; Wong DT Life Sci; 1986 Jan; 38(4):317-22. PubMed ID: 3753738 [TBL] [Abstract][Full Text] [Related]
3. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats. Fuller RW; Hemrick-Luecke SK; Wong DT; Pearson D; Threlkeld PG; Hynes MD J Pharmacol Exp Ther; 1983 Nov; 227(2):354-9. PubMed ID: 6138425 [TBL] [Abstract][Full Text] [Related]
4. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide. Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215 [TBL] [Abstract][Full Text] [Related]
5. Time course of the changes in striatal acetylcholine levels induced by pergolide and haloperidol after lesion of the nigrostriatal dopaminergic pathways in the rat. Fage D; Guerin B; Feuerstein C; Demenge P; Scatton B Brain Res; 1984 Sep; 310(2):379-83. PubMed ID: 6488029 [TBL] [Abstract][Full Text] [Related]
6. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. Claustre Y; Fage D; Zivkovic B; Scatton B J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197 [TBL] [Abstract][Full Text] [Related]
7. LY141865, a D2-dopamine agonist, increases acetylcholine concentration in rat corpus striatum. Wong DT; Bymaster FP J Pharm Pharmacol; 1983 May; 35(5):328-9. PubMed ID: 6134807 [No Abstract] [Full Text] [Related]
8. Decrease in hypothalamic epinephrine concentration and other neurochemical changes produced by quinpirole, a dopamine agonist, in rats. Fuller RW; Hemrick-Luecke SK J Neural Transm; 1985; 61(3-4):161-73. PubMed ID: 3157777 [TBL] [Abstract][Full Text] [Related]
9. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Onali P; Olianas MC; Gessa GL Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites. Wong DT; Threlkeld PG; Bymaster FP Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223 [TBL] [Abstract][Full Text] [Related]
11. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. DeBoer P; Abercrombie ED J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558 [TBL] [Abstract][Full Text] [Related]
12. Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists. Fuller RW; Hemrick-Luecke SK; Perry KW; Toomey RE J Pharm Pharmacol; 1985 Apr; 37(4):268-70. PubMed ID: 2860228 [TBL] [Abstract][Full Text] [Related]
13. Effects of specific D-1 and D-2 dopamine agonists (LY141865 and SKF-38393) and pergolide on urinary output of rats. Leander JD Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):290-5. PubMed ID: 2962555 [TBL] [Abstract][Full Text] [Related]
14. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Meller E; Kuga S; Friedhoff AJ; Goldstein M Life Sci; 1985 May; 36(19):1857-64. PubMed ID: 3157851 [TBL] [Abstract][Full Text] [Related]
15. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
16. Hypophysectomy fails to affect the supersensitivity of striatal dopamine target cells induced by prolonged haloperidol treatment. Scatton B; Fage D Eur J Pharmacol; 1984 Feb; 98(1):1-7. PubMed ID: 6538845 [TBL] [Abstract][Full Text] [Related]
17. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions. Ajima A; Yamaguchi T; Kato T Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213 [TBL] [Abstract][Full Text] [Related]
18. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats. Pollack AE; Yates TM Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212 [TBL] [Abstract][Full Text] [Related]
19. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine. Clark D; Salah RS; Galloway MP Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667 [TBL] [Abstract][Full Text] [Related]
20. Dopamine D(1) receptor-mediated control of striatal acetylcholine release by endogenous dopamine. Acquas E; Di Chiara G Eur J Pharmacol; 1999 Oct; 383(2):121-7. PubMed ID: 10585525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]